{"created":"2023-07-25T10:23:32.537046+00:00","id":3227,"links":{},"metadata":{"_buckets":{"deposit":"7d3c0a98-5acb-4d6c-9ffa-b7d18afc6e71"},"_deposit":{"created_by":18,"id":"3227","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"3227"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00003227","sets":["611:862:863:1161"]},"author_link":["10234","10221","11070","10235","10232","10238","10230","6135","10237","11071","9468","10239","10231","10236","11072","11073","9499"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3/4","bibliographicPageEnd":"109","bibliographicPageStart":"101","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"秋田医学"},{"bibliographic_title":"AKITA JOURNAL OF MEDICINE","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"内容記述（抄録）","attribute_value_mlt":[{"subitem_description":"AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1.\nMETHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016.　We followed them until 24 weeks after the end of treatment.\nRESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%.　In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate.　In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate.　The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients.　10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom.　Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events.\nCONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events.","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.20569/00003587","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"秋田医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00009294","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03866106","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"AJIMINE, Takuma"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHSHIMA, Shigetoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"GOTO, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOMATSU, Masafumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKANE, Kunio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAGISAWA, Hitoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Goto, Mitsuo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKAJIMA, Kou"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miura, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUNAOKA, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HOSHINO, Takao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KURAMITSU, Tomoyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUJISHIMA, Yuukou"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"WATANABE, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Segawa, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inomata, Masaaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"IIJIMA, Katsunori"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-05"}],"displaytype":"detail","filename":"akitai44_3_4(101).pdf","filesize":[{"value":"787.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"akitai44_3_4(101)","url":"https://air.repo.nii.ac.jp/record/3227/files/akitai44_3_4(101).pdf"},"version_id":"8152508c-aee3-4648-b824-1e91e8d90e43"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"hepatitis C virus","subitem_subject_scheme":"Other"},{"subitem_subject":"interferon free","subitem_subject_scheme":"Other"},{"subitem_subject":"daclatasvir","subitem_subject_scheme":"Other"},{"subitem_subject":"asunaprevir","subitem_subject_scheme":"Other"},{"subitem_subject":"α fetoprotein","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1"}]},"item_type_id":"10001","owner":"18","path":["1161"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-05"},"publish_date":"2018-07-05","publish_status":"0","recid":"3227","relation_version_is_last":true,"title":["EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-25T11:24:19.342262+00:00"}